Nanoparticles target intimal macrophages in atherosclerotic lesions

Nanomedicine. 2021 Feb:32:102346. doi: 10.1016/j.nano.2020.102346. Epub 2020 Nov 29.

Abstract

Oxidized phosphatidylcholines (oxPCs) enriched on the oxidized LDL (oxLDL) surface are responsible ligands for binding oxLDL to the CD36 receptor of intimal macrophages in atherosclerotic lesions. We synthesized liposome-like nanoparticles (NPs) using soy phosphatidylcholine and incorporated 1-palmitoyl-2-(4-keto-dodec-3-enedioyl) phosphatidylcholine, a type of oxPCs, on their surface to make ligand-NP (L-NPs). The objectives of this study were to measure and compare their binding affinity to and uptake by primary mouse and THP-1 derived macrophages, and to determine their target specificity to intimal macrophages in aortic lesions in LDL receptor null (LDLr-/-) mice. All in vitro data demonstrate that L-NPs had a high binding affinity to macrophage CD36 receptor. L-NPs had 1.4-fold higher accumulation in aortic lesion areas than NPs. L-NPs co-localized with intimal macrophages and CD36 receptors in the aortic lesions. This target delivery approach may portend a breakthrough in molecular imaging and targeted treatment of atherosclerosis.

Keywords: 1-Palmitoyl-2-(4-keto-dodec-3-enedioyl) phosphatidylcholine; Atherosclerosis; CD36 receptors; Macrophages; Nanoparticles; Targeted delivery.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Animals
  • Aorta / pathology
  • Atherosclerosis / pathology*
  • CD36 Antigens / metabolism
  • Humans
  • Ligands
  • Liposomes
  • Macrophages / metabolism*
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Nanoparticles / chemistry*
  • Nanoparticles / ultrastructure
  • Receptors, LDL / deficiency
  • Receptors, LDL / metabolism
  • THP-1 Cells
  • Tunica Intima / pathology*

Substances

  • CD36 Antigens
  • Ligands
  • Liposomes
  • Receptors, LDL